These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma]. Le Brun IC; Benderra MA Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742 [No Abstract] [Full Text] [Related]
4. Is there a role for pembrolizumab beyond progression in urothelial carcinoma? Taguchi S; Kawai T; Nakagawa T; Kume H BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020 [No Abstract] [Full Text] [Related]
10. Pembrolizumab for the treatment of bladder cancer. Sundahl N; Rottey S; De Maeseneer D; Ost P Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318 [TBL] [Abstract][Full Text] [Related]
11. Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma. Yumioka T; Honda M; Shimizu R; Teraoka S; Yamaguchi N; Kawamoto B; Iwamoto H; Morizane S; Hikita K; Takenaka A Anticancer Res; 2021 Nov; 41(11):5767-5773. PubMed ID: 34732450 [TBL] [Abstract][Full Text] [Related]
12. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria. Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001 [TBL] [Abstract][Full Text] [Related]
14. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer. Vogl UM; Testi I; De Santis M Eur Urol Focus; 2024 Mar; 10(2):217-218. PubMed ID: 38582643 [TBL] [Abstract][Full Text] [Related]
15. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape. Brown JR; Koshkin VS Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658 [TBL] [Abstract][Full Text] [Related]
16. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Culine S Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527 [No Abstract] [Full Text] [Related]
19. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind? Bellmunt J; Nadal R Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Tripathi A; Plimack ER Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]